Search Results - pancreatic+cancer

5 Results

Sort By:

CD206 Small Molecule Modulators, Their Use and Methods for Preparation

Summary: The NCI is seeking licensing partners and/or collaborators to perform IND enabling studies to translate the anti-CD206 small molecule into a therapeutic for CD206 expressing cancers. Description of Technology: Pancreatic ductal adenocarcinoma (PDA) accounts for more than 90% of pancreatic cancer cases, and it is one of the most aggressive...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Udo Rudloff, Juan Marugan, Xin Hu, Raul Calvo, Noel Southall, Bolormaa Baljinnyam

Keywords(s): CD206, M1 Macrophage, M2 Macrophage, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDA, Rudloff, TAM, Tumor-Associated Macrophages

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

Synthetic lipopeptide inhibitors of RAS oncoproteins

Abstract: It is well known that overactive Ras signaling is linked to many forms of cancer, and despite intensive efforts worldwide to develop effective inhibitors of Ras, to date there is no anti-Ras inhibitor in clinical use. Researchers at the NCI’s Cancer and Inflammation Program, in collaboration with scientists at Vanderbilt University and the...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Nadya Tarasova, Sergey Tarasov, Vadim Gaponenko, Joseph Kates, Michael Dean, Alla Ivanova

Keywords(s): COLON, LUNG, MULTIPLE MYELOMA, Pancreatic Cancer, RAS, THYROID CANCER

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors

Summary: The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies. Description of Technology: CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Mitchell Ho, Brad St. Croix, Ruixue Wang, Dan Li

Keywords(s): ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors

Description of Technology: Pancreatic cancer is the fourth most common cause of cancer deaths in the U.S. The overall 5-year survival rate is 8.5%. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan protein overexpressed in pancreatic cancer. Due to preferential expression, GPC1 represents a potential candidate for targeted therapy for...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Mitchell Ho, Jessica Hong

Keywords(s): cancer therapeutic, CAR, chimeric antigen receptor, Glypican-1, GPC-1, Hinge, HO, IgG4, Immunoglobulin subclass 4, NANOBODY, Pancreatic Cancer, Single Domain Antibody

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

High Affinity Monoclonal Antibodies Targeting Glypican-1

Abstract: Pancreatic cancer is the fourth most common cause of death from cancer in the U.S. The overall 5-year survival rate for this disease is 8.5%. Glypican-1 (GPC1), a cell surface heparan sulfate proteoglycan protein that is overexpressed in pancreatic cancer. Due to this preferential expression, GPC1 represents a potential candidate for targeted...

Published: 5/14/2025 | Updated: 8/2/2023 | Inventor(s): Mitchell Ho, Nan Li

Keywords(s): ADC, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-1, GPC1, HO, Immunotoxin, NANOBODY, Pancreatic Cancer, Recombinant Immunotoxin, Rit, Single Domain Antibody

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics